Key Quantitative Figures
- Fine amount: ₹1,80,000 (Rupees One Lakh Eighty Thousand only) per exchange, excluding GST
- Total fine paid: ₹3,60,000 (excluding GST) to both BSE and NSE
- Fine as percentage of market capitalisation: 0.000269%
Dates of Action
- Date of receipt of order: August 25, 2026 (received around 06:57 PM from BSE and 10:41 PM from NSE)
- Disclosure date: November 06, 2026
- Payment date: Disclosed as duly paid but specific date not mentioned
Parties Involved
- Regulatory authorities: BSE Limited (BSE) and National Stock Exchange of India Limited (NSE)
- Listed entity: Bliss GVS Pharma Limited
- Company representative: Aditi H. Bhatt, Company Secretary & Compliance Officer
Violation Details
- Regulation violated: Regulation 17(1) of SEBI Listing Regulations
- Nature of violation: Non-compliance with requirements pertaining to the composition of the Board
- Specific failure: Failure to appoint woman director
Financial Impact
- Quantifiable impact: Nil, except to the extent of the fine imposed by BSE and NSE
- No operational impact disclosed
- No other financial activities affected
Reason for Delay in Disclosure
The delay in filing the disclosure under Regulation 30 was inadvertent and occurred on account of the time taken for internal coordination and verification of the relevant information pertaining to the fines imposed by the Stock Exchanges. Consequently, the disclosure could not be made within the prescribed timeline. The Company regrets the delay and has taken due note of the same.
Remedial Measures
The Company is strengthening its internal reporting and monitoring mechanisms to ensure timely identification and disclosure of material events and information in compliance with the applicable provisions of the SEBI Listing Regulations.